HomeStock ScreenerEris Lifesciences

Eris Lifesciences Current Share Price | Eris Lifesciences Stock Screener

ERIS Pharmaceuticals
Live Share Price NSE
₹1321.30
▲ 10.60 (0.81%)
2026-09-18 00:00:00
Live Share Price BSE
₹1321.25
▲ 11.60 (0.89%)
2026-09-18 00:00:00
As of September 18, 2026, the live Eris Lifesciences share price (NSE: ERIS) is ₹1,321.30 on NSE and ₹1,321.25 on BSE, up 0.81% from the previous close, with shares trading between ₹1,303.10 and ₹1,355.10 in today's trading session, and a 52-week range of ₹1,271.00–₹1,701.30. Browse Eris Lifesciences annual reports to support your investment research. Use the Eris Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Eris Lifesciences Market Cap ₹18,153.70 Cr.
ERIS P/E Ratio (TTM) 28.25
Eris Lifesciences P/B Ratio 4.81
EPS (TTM) ₹45.33
Dividend Yield 0.53%
Debt to Equity 0.72
ERIS 52 Week High ₹1701.30
Eris Lifesciences 52 Week Low ₹1271.00
Operating Margin 34.00%
Profit Margin 16.42%
ERIS Revenue (TTM) ₹871.00
EBITDA ₹294.00
Net Income ₹143.00
Total Assets ₹7,366.00
Total Equity ₹3,896.00

Eris Lifesciences Current Share Price Chart

Track the current Eris Lifesciences share price and stock price with an interactive chart. Analyse ERIS price trends, trading volume, historical performance, and volatility across different timeframes — the complete Eris Lifesciences stock quote in one place.

Eris Lifesciences Company Profile - Fundamental Screener

Screen Eris Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ERIS shares.
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands...more
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO Amit Indubhushan Bakshi
ISIN INE406M01024

Eris Lifesciences Balance Sheet Screener

Screen ERIS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017
Assets
Total Assets 7,366 7,036 7,041 3,667 2,272 1,835 1,552 1,554 1,460 727
Current Assets 1,540 1,226 2,302 765 627 467 480 582 299 216
Fixed Assets 5,188 5,307 4,319 2,568 918 854 875 761 771 232
Liabilities
Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 1,393 2,380 1,286 1,003 164 91 91 79 349 60
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 3,896 3,272 3,222 2,221 1,908 1,576 1,296 1,169 886 591
Share Capital 14 14 14 14 14 14 14 14 14 14
Reserves & Surplus 3,889 2,841 2,573 2,182 1,894 1,563 1,283 1,137 848 553

Eris Lifesciences Income Statement Screener - Profit & Revenue Analysis

Screen Eris Lifesciences income statement and profit fundamentals. Analyze ERIS quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Eris Lifesciences share price evaluation.
Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec
Revenue 871 755 801 793 775 711 726 744 717 562 488 504 461 398 420
Expenses 577 484 543 504 496 453 477 477 470 403 311 324 297 284 286
EBITDA 294 270 258 289 279 258 249 267 248 160 177 180 164 114 134
Operating Profit % 34.00% 36.00% 32.00% 36.00% 36.00% 36.00% 34.00% 35.00% 34.00% 26.00% 36.00% 35.00% 35.00% 28.00% 32.00%
Depreciation 72 70 70 69 71 77 81 81 76 54 46 42 41 35 30
Interest 47 46 49 50 49 54 57 60 60 33 18 16 17 9 3
Profit Before Tax 180 159 145 173 161 129 116 129 116 77 116 126 113 76 107
Tax 36 -120 37 38 36 27 29 33 26 -3 14 4 19 14 6
Net Profit 143 279 109 135 125 102 87 96 90 80 102 122 94 62 100
EPS 10.28 20.60 7.32 8.82 8.66 6.90 6.16 6.73 6.11 5.22 7.55 9.08 6.97 4.81 7.49

Eris Lifesciences Cash Flow Screener - Liquidity Fundamentals

Screen ERIS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March
Operating Activities 538 1,065 486 292 378 375 271 223 235 200
Investing Activities -370 -78 -1,828 -975 -320 -323 123 -5 -590 -185
Financing Activities -314 -881 1,380 688 -45 -82 -335 -221 363 -24
Net Cash Flow -145 106 38 5 14 -30 60 -3 8 -8

Eris Lifesciences Shareholding Pattern Screener

See Eris Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check Eris Lifesciences promoter holding and ownership changes for ERIS on TickJournal.
Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun
Promoter Holding 53.92% 54.14% 54.85% 54.83% 54.85% 54.85% 54.90% 54.88%
FII Holding 6.39% 5.75% 8.43% 8.40% 7.21% 6.85% 14.27% 14.59%
DII Holding 20.35% 20.72% 18.07% 18.17% 19.36% 20.32% 15.63% 16.23%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 10.06% 10.10% 9.16% 9.12% 9.12% 8.51% 14.24% 13.53%
Other Holding 9.26% 9.29% 9.49% 9.47% 9.45% 9.48% 0.95% 0.77%
Shareholder Count 51,656 50,798 50,087 52,225 59,438 54,713 51,753 44,176

Eris Lifesciences Share Dividend Screener - Share Yield Analysis

Check Eris Lifesciences dividend history with payout and yield data. View Eris Lifesciences dividend details including ex-dates and amounts for ERIS stock.
Period Dividend Per Share Dividend Yield
2026-March ₹7.21 0.53%
2025-March ₹7.35 0.57%
2024-March ₹0.00 0.00%
2023-March ₹7.35 0.87%
2022-March ₹6.01 1.05%
2021-March ₹5.50 0.80%
2020-March ₹2.87 0.47%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Eris Lifesciences Stock Index Membership

See which indices include Eris Lifesciences stock. Check ERIS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP

Eris Lifesciences Market Events Screener - Corporate Actions

Get Eris Lifesciences corporate actions including splits, bonuses, and buybacks. Check Eris Lifesciences stock events that may affect ERIS share price.
Announcement Date Record Date Event Type Information Price Impact
2026-09-25 2026-09-25 Annual General Meeting NA 3.03%
2026-07-29 2026-07-29 Quarterly Result Announcement NA -3.46%
2026-05-29 2026-05-29 Dividend ₹ 7.21 /share 1.09%
2026-05-20 2026-05-20 Quarterly Result Announcement NA -2.81%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 6.90%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -0.28%
2025-08-05 2025-08-05 Quarterly Result Announcement NA 0.55%
2025-07-25 2025-07-25 Annual General Meeting NA 6.29%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 4.50%
2025-02-13 2025-02-13 Dividend ₹ 7.35 /share -10.84%
2025-02-04 2025-02-04 Quarterly Result Announcement NA 7.93%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -3.41%
2024-09-25 2024-09-25 Annual General Meeting NA -9.82%
2022-08-11 2022-08-16 Dividend ₹ 7.35 /share -0.23%
2021-08-05 2021-08-06 Dividend ₹ 6.01 /share 0.77%

Eris Lifesciences Competitors Screener - Peer Comparison

Screen ERIS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 440,278 36.48 61,674 12.69% 11,565 34.00
Divis Laboratories 244,178 84.64 11,067 13.95% 2,568 63.65
Torrent Pharmaceuticals 184,478 87.77 13,886 20.34% 2,138 52.16
Zydus Life Science 110,585 24.32 27,658 17.64% 5,026 45.64
Cipla 109,140 32.86 29,045 2.24% 3,870 35.27
Laurus Labs 104,025 97.64 6,868 22.01% 890 68.28
Dr Reddys Laboratories 95,570 30.44 35,059 3.90% 4,158 47.72
Aurobindo Pharma 95,513 25.98 34,145 5.56% 3,503 57.04
Lupin 94,336 17.27 29,039 26.75% 5,356 28.17
Mankind Pharma 94,184 45.49 14,636 14.85% 1,938 37.57

Eris Lifesciences Company Announcements - News Screener

Screen ERIS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-09-17 Announcement under Regulation 30 (LODR)-Resignation of Director -
2026-09-16 Rumour Verification - Regulation 30(11) -
2026-09-15 Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Availing Term Loan From Axis Bank -
2026-09-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-03 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-02 Business Responsibility and Sustainability Reporting (BRSR) -
2026-09-02 Reg. 34 (1) Annual Report. -
2026-09-02 Annual General Meeting Of The Company Scheduled On September 25 2026 -
2026-08-31 Board Meeting Outcome for Outcome For Board Meeting -
2026-08-24 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-06 Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Availing Working Capital Term Loan From Axis Bank -
2026-08-04 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-07-30 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-07-30 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-07-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-07-29 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-07-29 Financial Results For The Quarter Ended June 30 2026 -